Impact of MDM2 promoter SNP55 (rs2870820) on risk of endometrial and ovarian cancer

References

• Bai, J., et al., 2009. Cigarette smoking, MDM2 SNP309, gene-environment interactions, and lung cancer risk: a meta-analysis. Journal of toxicology and environmental health. Part A, 72 (11-12), 677–682.
   PubMed Web of Science ®Google Scholar
• Barak, Y., et al., 1994. Regulation of mdm2 expression by p53: alternative promoters produce transcripts with nonidentical translation potential. Genes & development, 8 (15), 1739–1749.
   PubMed Web of Science ®Google Scholar
• Berwick, M., et al., 2007. Genetic heterogeneity among Fanconi anemia heterozygotes and risk of cancer. Cancer research, 67 (19), 9591–9596.
   PubMed Web of Science ®Google Scholar
• Bonadona, V., et al., French Cancer Genetics Network, 2011. Cancer risks associated with germline mutations in MLH1, MSH2, and MSH6 genes in Lynch syndrome. JAMA, 305 (22), 2304–2310.
   PubMed Web of Science ®Google Scholar
• Bond, G.L., et al., 2004. A single nucleotide polymorphism in the MDM2 promoter attenuates the p53 tumor suppressor pathway and accelerates tumor formation in humans. Cell, 119 (5), 591–602.
   PubMed Web of Science ®Google Scholar
• Bond, G.L., et al., 2006a. MDM2 SNP309 accelerates tumor formation in a gender-specific and hormone-dependent manner. Cancer research, 66 (10), 5104–5110.
   PubMed Web of Science ®Google Scholar
• Bond, G.L., et al., 2006b. MDM2 SNP309 accelerates colorectal tumour formation in women. Journal of medical genetics, 43 (12), 950–952.
   PubMed Web of Science ®Google Scholar
• De Voer, R.M., et al., 2015. Deleterious germline BLM mutations and the risk for early-onset colorectal cancer. Scientific reports, 5, 14060.
   PubMed Web of Science ®Google Scholar
• Economopoulos, K.P. and Sergentanis, T.N., 2010. Differential effects of MDM2 SNP309 polymorphism on breast cancer risk along with race: a meta-analysis. Breast cancer research and treatment, 120 (1), 211–216.
   PubMed Web of Science ®Google Scholar
• Gallegos-Arreola, M.P., et al., 2017. Association of the Del1518 promoter (rs3730485) polymorphism in the MDM2 gene with breast cancer in a Mexican Population. Ann clin lab sci, 47 (3), 291–297.
   PubMed Web of Science ®Google Scholar
• Gansmo, L.B., et al., 2016. Associations between the MDM2 promoter P1 polymorphism del1518 (rs3730485) and incidence of cancer of the breast, lung, colon and prostate. Oncotarget, 7 (19), 28637–28646.
   PubMedGoogle Scholar
• Gansmo, L.B., et al., 2017. MDM2 promoter polymorphism del1518 (rs3730485) and its impact on endometrial and ovarian cancer risk. BMC cancer, 17 (1), 97
   PubMedGoogle Scholar
• Haupt, Y., et al., 1997. Mdm2 promotes the rapid degradation of p53. Nature, 387 (6630), 296–299.
   PubMed Web of Science ®Google Scholar
• Helwa, R., et al., 2016. MDM2 promoter SNP55 (rs2870820) affects risk of colon cancer but not breast-, lung-, or prostate cancer. Scientific reports, 6, 33153.
   PubMed Web of Science ®Google Scholar
• Honda, R., et al., 1997. Oncoprotein MDM2 is a ubiquitin ligase E3 for tumor suppressor p53. FEBS letters, 420 (1), 25–27.
   PubMed Web of Science ®Google Scholar
• Hu, Z., et al., 2006. Genetic variants in the MDM2 promoter and lung cancer risk in a Chinese population. International journal of cancer, 118 (5), 1275–1278.
   PubMed Web of Science ®Google Scholar
• Hu, Z., et al., 2007. MDM2 promoter polymorphism SNP309 contributes to tumor susceptibility: evidence from 21 case-control studies. Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology, 16 (12), 2717–2723.
   PubMed Web of Science ®Google Scholar
• Hua, W., et al., 2017. MDM2 promoter del1518 polymorphism and cancer risk: evidence from 22,931 subjects. OncoTargets and therapy, 10, 3773–3780.
   PubMed Web of Science ®Google Scholar
• Knappskog, S. and Lønning, P.E., 2011. MDM2 promoter SNP285 and SNP309; phylogeny and impact on cancer risk. Oncotarget, 2 (3), 251–258.
   PubMedGoogle Scholar
• Knappskog, S., et al., 2011. The MDM2 promoter SNP285C/309G haplotype diminishes Sp1 transcription factor binding and reduces risk for breast and ovarian cancer in Caucasians. Cancer cell, 19 (2), 273–282.
   PubMed Web of Science ®Google Scholar
• Knappskog, S., et al., Norwegian Breast Cancer Group trial NBCG VI, 2012a. MDM2 promoter SNP344T > A (rs1196333) status does not affect cancer risk. PLoS one, 7 (4), e36263.
   PubMed Web of Science ®Google Scholar
• Knappskog, S., et al., MoMaTEC study group, 2012b. SNP285C modulates oestrogen receptor/Sp1 binding to the MDM2 promoter and reduces the risk of endometrial but not prostatic cancer. European journal of cancer (Oxford, England : 1990), 48 (13), 1988–1996.
   PubMed Web of Science ®Google Scholar
• Knappskog, S., et al., 2014. Population distribution and ancestry of the cancer protective MDM2 SNP285 (rs117039649). Oncotarget, 5 (18), 8223–8234.
   PubMedGoogle Scholar
• Lalonde, M.-E., et al., 2012. Identification of functional DNA variants in the constitutive promoter region of MDM2. Human genomics, 6 (1), 15
   PubMedGoogle Scholar
• Lonning, P.E., et al., 2018. White blood cell BRCA1 promoter methylation status and ovarian cancer risk. Annals of internal medicine, 168 (5), 326–334.
   PubMed Web of Science ®Google Scholar
• Moazeni-Roodi, A., et al., 2019. The 40bp indel polymorphism of MDM2 increase the risk of cancer: an updated meta-analysis. Molecular biology research communications, 8 (1), 1–8.
   PubMed Web of Science ®Google Scholar
• Momand, J., et al., 1998. The MDM2 gene amplification database. Nucleic acids research, 26 (15), 3453–3459.
   PubMed Web of Science ®Google Scholar
• Naess, O., et al., 2008. Cohort profile: cohort of Norway (CONOR). International journal of epidemiology, 37 (3), 481–485.
   PubMed Web of Science ®Google Scholar
• Okamoto, K., et al., 2015. SNP55, a new functional polymorphism of MDM2-P2 promoter, contributes to allele-specific expression of MDM2 in endometrial cancers. BMC medical genetics, 16, 67.
   PubMed Web of Science ®Google Scholar
• Oliner, J.D., et al., 1992. Amplification of a gene encoding a p53-associated protein in human sarcomas. Nature, 358 (6381), 80–83.
   PubMed Web of Science ®Google Scholar
• O'mara, T.A., et al., 2018. Identification of nine new susceptibility loci for endometrial cancer. Nature communications., 9 (1), 3166.
   PubMedGoogle Scholar
• Ortiz, G.J., et al., 2018. Contrasting effects of an Mdm2 functional polymorphism on tumor phenotypes. Oncogene, 37 (3), 332–340.
   PubMed Web of Science ®Google Scholar
• Paulin, F.E., et al., 2008. MDM2 SNP309 is associated with high grade node positive breast tumours and is in linkage disequilibrium with a novel MDM2 intron 1 polymorphism. BMC cancer, 8, 281.
   PubMed Web of Science ®Google Scholar
• Phelan, C.M., et al., OPAL study group, 2017. Identification of 12 new susceptibility loci for different histotypes of epithelial ovarian cancer. Nature genetics, 49 (5), 680–691.
   PubMed Web of Science ®Google Scholar
• Wilkening, S., et al., 2007. MDM2 SNP309 and cancer risk: a combined analysis. Carcinogenesis, 28 (11), 2262–2267.
   PubMed Web of Science ®Google Scholar
• Zauberman, A., et al., 1995. A functional p53-responsive intronic promoter is contained within the human mdm2 gene. Nucleic acids research, 23 (14), 2584–2592.
   PubMed Web of Science ®Google Scholar